Smolewska E.

Ostatnio edytowane

1. Pharmacokinetics (PK) and pharmacodynamics (PD) of tocilizumab (TCZ) in polyarticular-course juvenile idiopathic arthritis (pcJIA). [AUT.] X. ZHANG, J. HSU, H. BRUNNER, F. DE BENEDETTI, C. LE GALLO, Z. ZUBER, R. CUTTICA, V. KELTSEV, R. XAVIER, I. C. PENEDES, N. RUBIO-PÉREZ, V. CHASNYK, G. HORNEFF, V[IOLETTA] OPOKA-WINIARSKA, P. QUARTIER, C. SILVA, A. SPINDLER, E. BAILDAM, M. L. GAMIR, A. MARTIN, D. A. SIRI, E. SMOLEWSKA, D. LOVELL, N. RUPERTO, A. MARTINI. Clin. Pharmacol. Ther. 2013 vol. 93 nr S1 s. S88-S89, Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) : Quantitative systems pharmacology an integrating framework for translational medicine pre-conference. Indianapolis, March, 05-09, 2013. [Abstr.]. DOI: 10.1038/clpt.2012.258
2. Safety of the COVID-19 vaccination in children with juvenile idiopathic arthritis - a questionnaire study from two pediatricrheumatology centers in Poland. [AUT.] V[IOLETTA] OPOKA-WINIARSKA, J. LIPIŃSKA, K. ORCZYK, A. MICHALAK, J. BURZYŃSKI, O. KĄDZIOŁKA, E. SMOLEWSKA. Pediatr. Rheumatol. [online] 2022 vol. 20 suppl. 2 s. 256-257, Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022). Prague, 20-23 September 2022. [Abstr.] [przeglądany 22 listopada 2022]. Dostępny w: https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-022-00729-z. DOI: 10.1186/s12969-022-00729-z